Stock Groups

Regeneron Pharma Earnings, Revenue Beat in Q4 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Regeneron Pharma Earnings, Revenue Beat in Q4

Regeneron Pharma (NASDAQ) reported Friday that the fourth quarter beat analyst forecasts. The company’s revenue exceeded expectations.

Regeneron Pharma posted earnings per share (EPS) of $23.72 on revenues of $4.95B. Investing.com polled analyst to predict EPS of $23.72 on revenues of $4.95B.

Regeneron Pharma shares fell 1.71% over the first year. This is still 9.60% off its 52 week peak of $686.62, which was set September 3, 2021. They are outperforming the S&P 500 which is down 6.06% from the start of the year.

Regeneron Pharma’s earnings are in line with other healthcare sector leaders this month

Regeneron Pharma’s January 19 earnings beat was achieved by UnitedHealth, who reported EPS at $4.48 per share on revenues of $73.74B. That compares with forecasts for EPS at $4.3 on revenues of $72.98B.

J&J had beat expectations on January 25 with fourth quarter EPS of $2.13 on revenue of $24.8B, compared to forecast for EPS of $2.12 on revenue of $25.28B.

You can keep up-to date on the latest earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]